Ajanta Tadalafil Products

Ajanta Pharma currently has tadalafil products in the United States, including Cialis-reference generic tablets for erectile dysfunction and benign prostatic hyperplasia and a separate Adcirca-reference product for pulmonary arterial hypertension. The shared ingredient is tadalafil, but the product identity, indication, strengths, and reference drug must be checked separately.

Ajanta has also been associated historically with brand names such as Tadalis and Apcalis. Those names should not automatically be presented as current Ajanta products. Current Ajanta Pharma USA records provide the clearest basis for the present U.S. portfolio, while older or market-specific names require their own current authoritative verification.

Tadalafil as an Active Ingredient

Tadalafil is a PDE5 inhibitor used in more than one prescription-product category. Cialis-reference tadalafil products may be labeled for erectile dysfunction, benign prostatic hyperplasia, or both. Adcirca-reference tadalafil is used for pulmonary arterial hypertension.

Because the same active ingredient appears in both categories, the word “tadalafil” alone does not tell a buyer which product is being discussed. Strength, label, reference drug, NDC, and indication all matter.

Ajanta Tadalafil Products

Ajanta Pharma USA’s current catalog lists Tadalafil Tablets, USP in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths within the Cialis-reference product family. The current 20 mg Cialis-reference product page identifies erectile dysfunction and benign prostatic hyperplasia as the indication category and lists an AB1 therapeutic-equivalence code.

Ajanta Pharma USA also lists a separate Tadalafil Tablets, USP 20 mg product referencing Adcirca. That product is labeled for pulmonary arterial hypertension and has a separate NDC and AB2 therapeutic-equivalence code.

Those current U.S. records provide a reliable basis for Ajanta tadalafil product identification without relying on older brand lists.

Ajanta Tadalafil in the United States

The current Ajanta Pharma USA product catalog shows the Cialis-reference tadalafil series in four strengths:

• 2.5 mg tablets;
• 5 mg tablets;
• 10 mg tablets;
• 20 mg tablets.

The current Ajanta 20 mg Cialis-reference product page identifies the tablet as an oral prescription product for ED/BPH and provides U.S. NDC and package information. The site uses the generic product name rather than presenting an overseas brand as the U.S. identity.

The separate Ajanta 20 mg Adcirca-reference product page identifies pulmonary arterial hypertension as its indication and carries a different U.S. product record. This distinction is not cosmetic. A user should not treat the PAH product as an ED substitute simply because both products contain tadalafil and both can be 20 mg tablets.

Market-Specific Tadalafil Brands

Older product and commercial references frequently associate Ajanta with names such as Tadalis and Apcalis. Their current status needs separate verification rather than being assumed from historical association.

Tadalis remains a current tadalafil brand in Australian government medicine records, including TADALIS 20 listings for pulmonary arterial hypertension. Historical U.S. International Trade Commission material also associated “Tadalis” tablets with Ajanta Pharma during a much older tadalafil patent/import investigation. However, the current Australian public records reviewed for this update do not by themselves establish that the currently listed Tadalis product is manufactured or sponsored by Ajanta.

Accordingly, this page does not present Tadalis as a current Ajanta brand. The historical association is relevant because the name has appeared in connection with Ajanta products, but it does not establish current manufacture or sponsorship. A current Ajanta-manufacturer claim would require a current manufacturer or regulator record tying the exact product to Ajanta.

Apcalis was also present in older commercial material, but a current authoritative source confirming its present Ajanta product status was not identified. It is therefore not listed as a current Ajanta tadalafil product here.

Strengths, Forms and Indications

Current Ajanta Pharma USA records support tadalafil tablets in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths in the Cialis-reference category. A separate 20 mg tablet exists in the Adcirca-reference PAH category.

All currently verified Ajanta U.S. tadalafil examples used on this page are tablets. The same strength can appear in different indication categories, so strength alone does not identify the product.

For a commercially useful product check, record:

• exact generic or brand name;
• strength;
• dosage form;
• reference drug if shown;
• indication on the current label;
• NDC or national registration number;
• country or market.

Those details make it possible to distinguish a Cialis-reference generic from a PAH product before any availability or price question is asked.

Reading the Ajanta USA Tadalafil Catalog Correctly

Ajanta Pharma USA’s catalog is useful because it separates tadalafil products by reference drug and indication rather than grouping every 20 mg tablet together. The Cialis-reference 20 mg page identifies ED/BPH, an AB1 therapeutic-equivalence code, and its own NDC. The Adcirca-reference 20 mg page identifies pulmonary arterial hypertension, an AB2 code, and a different NDC.

For a pre-purchase or prescription-access question, those fields are more useful than tablet color alone. They allow a pharmacy, patient, or reviewer to establish which regulatory product family is being discussed before comparing pack size or availability.

Why Old Ajanta Brand Names Need Separate Verification

Tadalis and Apcalis demonstrate the difference between historical brand association and current product verification. Historical legal or commercial records can explain why a name became associated with Ajanta, but they do not automatically prove who manufactures or sponsors the product today.

Current Australian government sources still list Tadalis as a tadalafil brand, but those current records do not provide a verified Ajanta manufacturer/sponsor link. The useful distinction is to preserve the historical product context while stating clearly what can and cannot be verified today. Apcalis is handled even more conservatively because a current preferred-source Ajanta relationship was not established.

How to Verify a Market-Specific Ajanta Tadalafil Claim

When a seller or article presents a market-specific Ajanta tadalafil name, check the national regulator for that exact brand and strength, then verify the manufacturer or sponsor field. If the claim concerns a U.S. Ajanta product, use the current Ajanta Pharma USA catalog and FDA/DailyMed records. If those sources point to a different product identity, the older brand name should not override the current record.

Regulatory Status and Market Differences

Ajanta Pharma USA currently presents its U.S. portfolio as FDA-approved generic products. Product-specific pages provide NDCs, strengths, reference brands, indications, and therapeutic-equivalence codes. That is the appropriate level of evidence for describing current U.S. Ajanta tadalafil.

It would be incorrect to extend those U.S. approvals to old Ajanta brand names from other markets. Ingredient approval and manufacturer approval are not blanket approvals for every product name that has ever contained tadalafil.

The same caution applies in reverse. A brand that is registered in Australia or another country does not automatically become an FDA-approved U.S. product. Market status should be checked with the regulator that governs the product where it is supplied.

Comparing Ajanta Tadalafil Products

For current Ajanta U.S. products, the most important comparison is between the Cialis-reference ED/BPH family and the Adcirca-reference PAH product.

• Ingredient: both contain tadalafil.
• Manufacturer/labeler group: both are represented in the Ajanta Pharma USA portfolio.
• Strengths: the Cialis-reference family includes 2.5 mg, 5 mg, 10 mg, and 20 mg; the verified Adcirca-reference product is 20 mg.
• Indication: ED/BPH versus pulmonary arterial hypertension.
• Reference drug: Cialis versus Adcirca.
• Regulatory record: separate NDCs and therapeutic-equivalence codes.

This comparison is more accurate than grouping every Ajanta tadalafil tablet under an “ED product” label. The current product page and prescription should determine which product is relevant.

Availability and Product Identification

Before asking whether an Ajanta tadalafil product can be filled, identify the exact U.S. generic or market-specific product. In the United States, an NDC from the current Ajanta Pharma USA page is especially useful. For a foreign brand, record the country, registration information, manufacturer, strength, and dosage form.

Current approval does not guarantee local pharmacy stock, and an old brand name found in search results may no longer be associated with the manufacturer or market it once appeared in. This page therefore does not claim that Paulsen’s Pharmacy currently stocks Ajanta tadalafil or any historical Ajanta tadalafil brand.

Pricing also depends on the exact product, quantity, pharmacy, insurance status, and market. No fixed price is published here because a durable authoritative price applicable across Ajanta tadalafil products was not identified.

More About Ajanta Pharma

For manufacturer-level information and navigation across the broader portfolio, see Ajanta Pharma.

Ajanta also has current U.S. generic sildenafil products, while its Kamagra brand is documented separately in at least one non-U.S. Ajanta market. See Ajanta sildenafil and Kamagra products for that distinct product family.

Reviewed by: Dr. Nancy Ann Curosh